Executive Summary
This week's digest highlights: In acute ischemic stroke management, glenzocimab shows promise when added to thrombolysis, but further validation is needed before altering current protocols. For patients with NF2-related schwannomatosis, salvage microsurgery after bevacizumab failure demonstrates potential, though results warrant confirmation through full-text analysis. In degenerative cervical myelopathy cases...
Owen briefs you on what matters in this week's digest.
Think chief-resident chalk talk: what matters, what changes practice, and where to spend your reading time.
Spine
Prospective Comparison of Posterior Decompression and ACDF for 1- to 2-level Degenerative Cervical Myelopathy.
Research • Spine • Spine • 2025-09-03
Preliminary evidence; confirm full-text methods and endpoints before changing practice.
OWhile ACDF shows greater improvement in pain and physical health for 1- to 2-level degenerative cervical myelopathy, posterior decompression may be more suitable for patients prioritizing social functioning, highlighting the need for individualized treatment plans despite the moderate evidence quality.
Study snapshot
Design
Prospective multicenter cohort study
Population
Patients with 1- to 2-level degenerative cervical myelopathy
Intervention
Posterior decompression without fusion
Comparator
Anterior cervical discectomy and fusion (ACDF)
Primary outcome
JOA score, VAS, JOACMEQ, SF-36 at 2 years
Why it matters
Before this study, evidence comparing posterior decompression and ACDF for 1- to 2-level degenerative cervical myelopathy was limited. This prospective cohort found that ACDF provided greater improvement in neck and arm pain and physical health, while posterior decompression improved social functioning; neurological recovery was similar. Surgeons should individualize approach based on patient symptoms: ACDF for predominant pain, posterior decompression for myelopathy with social concerns.
Practice change
May support individualized surgical approach based on pain versus social functioning priorities.
More context
Key details
- Prospective multicenter cohort from 10 Japanese institutions.
- Included 353 patients with 1- to 2-level DCM followed for 2 years.
- No significant differences in JOA scores or JOACMEQ domains.
- ACDF superior for neck pain, arm pain, and SF-36 physical domains.
- Posterior decompression superior for SF-36 social functioning.
High-yield
ACDF provided significantly better pain relief and physical health, while posterior decompression improved social functioning; neurological outcomes were comparable.
Clinical context
Both posterior decompression and ACDF are used for cervical myelopathy, but evidence for - to -level disease is limited.
Limitations
Non-randomized design with potential selection bias.Single-country study may limit generalizability.
Methodological critique
Non-randomized design may confound results despite adjustment.
Teaching pearl
For 1- to 2-level cervical myelopathy, ACDF is better for axial and radicular pain, while posterior decompression may be preferred if social functioning is a priority.
Funding and COI
Not stated
Functional
Pallidus internus versus subthalamic nucleus deep brain stimulation for Meige syndrome: a randomized, controlled, double-blind multicenter trial.
Research • Functional • Journal of neurosurgery • 2026-02-20
For Meige syndrome, both GPi and STN DBS are effective and safe; STN-DBS may be preferred for lower energy consumption.
OIn counseling patients with Meige syndrome considering deep brain stimulation, emphasize that while both GPi and STN targets provide similar motor improvements, STN-DBS may be more favorable due to its lower energy consumption, potentially enhancing battery longevity.
Study snapshot
Design
Randomized, double-blind, multicenter trial
Population
Patients with Meige syndrome (n=62)
Intervention
GPi-DBS
Comparator
STN-DBS
Primary outcome
Improvement in BFMDRS movement score at 12 months
Why it matters
Before this trial, the optimal DBS target for Meige syndrome was unclear, with both GPi and STN used empirically. This randomized, double-blind multicenter study directly compares GPi-DBS and STN-DBS, finding comparable motor improvement and safety profiles. Clinicians can now offer either target, but STN-DBS may be preferred for its lower energy requirements.
Practice change
Confirms current practice: both GPi and STN DBS are reasonable options for Meige syndrome.
More context
High-yield
See source article for primary outcome data.
Clinical context
Meige syndrome is a form of craniocervical dystonia for which DBS is an established treatment, but the optimal target (GPi vs STN) has been debated.
Limitations
Single-blind design may introduce bias in outcome assessment.Sample size relatively small (n=31 per group), limiting subgroup analyses.
Methodological critique
Double-blind design strengthens validity, but single-center recruitment may limit generalizability.
Teaching pearl
When counseling Meige syndrome patients for DBS, explain that both GPi and STN targets offer similar motor benefits; STN-DBS may be advantageous for battery longevity due to lower energy requirements.
Funding and COI
Not stated
General Neurosurgery
Biological and clinical implications of autologous bone flap preservation strategies after decompressive craniectomy: a systematic review and meta-analysis.
Research • General Neurosurgery • Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia • 2026-02-19
Both subcutaneous and cryogenic bone flap preservation are acceptable; subcutaneous may offer a slight advantage based on RCT data.
OSubcutaneous and cryogenic bone flap preservation methods yield similar outcomes, but subcutaneous storage may reduce infection and revision rates according to RCT data, warranting consideration in clinical practice despite the need for further high-quality trials.
Study snapshot
Design
Systematic review and meta-analysis
Population
Adults undergoing cranioplasty after decompressive craniectomy (811 patients)
Intervention
Subcutaneous bone flap preservation
Comparator
Cryogenic bone flap preservation
Primary outcome
Surgical site infection, revision surgery, bone flap resorption
Why it matters
Before this meta-analysis, evidence comparing subcutaneous vs cryogenic bone flap preservation was conflicting. This study synthesizes 7 studies (811 patients) and finds no significant difference in SSI, resorption, or revision rates overall, though RCT data favor subcutaneous preservation for infection and revision. Clinicians may consider subcutaneous preservation when feasible, but high-quality RCTs are still needed.
Practice change
Confirms current practice: either preservation method is reasonable, though subcutaneous may be slightly favored based on limited RCT data.
More context
Key details
- Systematic review and meta-analysis of 7 studies (337 subcutaneous, 474 cryogenic).
High-yield
Subcutaneous and cryogenic bone flap preservation show comparable outcomes overall, but RCT data suggest subcutaneous may reduce infection and revision risk.
Clinical context
Autologous bone flap preservation after decompressive craniectomy is standard, but the optimal method (subcutaneous vs cryogenic) remains debated.
Limitations
Most included studies were observational with serious risk of bias.Heterogeneity in definitions of outcomes and preservation techniques across studies.
Methodological critique
Stratification by study design appropriately addresses bias, but observational studies dominate the analysis.
Teaching pearl
When discussing bone flap preservation with patients, note that while overall outcomes are similar, randomized evidence suggests subcutaneous storage may lower infection and revision rates, though the quality of evidence is moderate.
Funding and COI
Not stated
Basic Science
The Potential of Magnetic Targeted Natural Killer Cell Therapy for Glioblastoma: An in Vivo Study of Natural Killer Cells Loaded With Low-Temperature Synthesized Folic Acid-Modified Superparamagnetic Iron Oxide Nanoparticles.
Research • Basic Science • Neurosurgery • 2025-09-19
Preclinical evidence; no immediate practice change pending clinical validation.
OWhile the use of folic acid-modified superparamagnetic iron oxide nanoparticles to enhance NK cell targeting in glioblastoma shows promise in preclinical models, clinicians should remain cautious and await robust clinical validation before considering any changes to treatment protocols.
Study snapshot
Design
Basic science (preclinical)
Population
GBM-bearing mice
Intervention
SPIONs-PEG-FA-loaded NK cells with external magnetic field
Comparator
None (single-arm preclinical study)
Primary outcome
Tumor targeting and cytolytic efficiency
Why it matters
1) Glioblastoma (GBM) is a highly malignant brain tumor with limited treatment options, and natural killer (NK) cell-based immunotherapy shows promise but faces challenges in tumor targeting. 2) This study suggests that folic acid-modified superparamagnetic iron oxide nanoparticles (SPIONs-PEG-FA) can magnetize NK cells, enabling magnetic field-guided accumulation at the tumor site while preserving cytotoxic activity against GBM cells in preclinical models. 3) This is a preclinical proof-of-concept; clinicians should await further validation before considering any practice change.
Practice change
Does not change current clinical practice but may inform future translational work.
More context
Key details
- SPIONs-PEG-FA were synthesized via PEGylation and coprecipitation, confirmed by XRD, FTIR, TEM, and DLS.
- In vitro studies showed safe uptake and retained cytolytic activity of NK cells against GBM cells.
- TEM verified cellular uptake of SPIONs-PEG-FA by NK cells.
- In vivo experiments in GBM-bearing mice showed improved tumor targeting under external magnetic field.
- Enhanced cytolytic efficiency and overall safety were observed.
- Magnetic field-guided NK cell therapy offers a strategy to overcome GBM treatment challenges.
High-yield
SPIONs-PEG-FA-loaded NK cells improved tumor targeting and cytolytic efficiency in GBM-bearing mice, representing a promising magnetic field-guided immunotherapy approach.
Clinical context
Glioblastoma is a highly malignant brain tumor with limited treatment options. NK cell-based immunotherapy shows promise but faces challenges in effective tumor targeting.
Limitations
Preclinical model only; results may not translate to human GBM.No quantitative data (e.g., effect sizes, P-values) provided to assess statistical significance.
Methodological critique
No quantitative results or statistical analyses reported; descriptive only.
Teaching pearl
Nanoparticle-based magnetization of immune cells is an emerging strategy to enhance tumor targeting; understanding the synthesis and characterization of such nanoparticles is key for evaluating preclinical immunotherapy studies.
Funding and COI
Not stated
Trials to Know
CORUS-LX System for Lumbar Interbody Fusion: Post-Market Safety and Effectiveness
Trial • Trials to Know • ClinicalTrials.gov • 2026-05-03
Why it matters
This trial evaluates the CORUS-LX System, a novel supplemental posterior fixation device, against standard techniques in patients undergoing lumbar interbody fusion for radiculopathy or degenerative disc disease. It addresses the need for evidence on whether this device improves fusion rates and clinical outcomes, potentially offering a new option for posterior stabilization.
Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Trial • Trials to Know • ClinicalTrials.gov • 2026-05-03
Why it matters
This first-in-human trial evaluates GLIX1, a novel agent for recurrent/progressive high-grade glioma, a population with limited effective options. The dose-finding design establishes safety and preliminary efficacy, potentially offering a new therapeutic avenue for neurosurgeons managing treatment-refractory glioblastoma.
More context
Key details
- Phase 1, recruiting
Cortical Stimulation to Treat Obsessive Compulsive Disorder
Trial • Trials to Know • ClinicalTrials.gov • 2026-05-03
Why it matters
This trial investigates cortical stimulation as an alternative to deep brain stimulation (DBS) for treatment-resistant obsessive-compulsive disorder (OCD). For neurosurgeons, it explores whether targeting prefrontal cortex (PFC) or anterior cingulate cortex (ACC) with cortical stimulation can achieve comparable efficacy to DBS with a less invasive approach, potentially expanding surgical options for OCD patients.
From the Preprint Wire
Dissociating stimulus encoding and task demands in ECoG responses from human visual cortex
Preprint • From the Preprint Wire • biorxiv • 2026-04-19
Why it matters
This unreviewed preprint uses intracranial ECoG to dissociate how high- and low-frequency neural activity in ventral temporal cortex separately encode visual input and task demands. For neurosurgeons planning electrode placements or interpreting intraoperative recordings, understanding these distinct neural signatures could improve functional mapping and cognitive monitoring.
More context
Key details
- ECoG recordings from two human participants during fixation and image categorization tasks with varying contrast.
- High-frequency activity increased with contrast and was further amplified by task demands ~200 ms after stimulus onset.
- Low-frequency activity showed contrast-independent decreases with greater task demands, suggesting a role in disinhibition.
- Findings align with prior fMRI BOLD results but provide direct electrophysiological evidence for frequency-specific task effects.
Frontal TBI Reduces Cue Sensitivity and Remodels Nucleus Accumbens
Preprint • From the Preprint Wire • biorxiv • 2026-04-19
Why it matters
This unreviewed preprint suggests that frontal traumatic brain injury disrupts how the brain processes reward-predictive cues by remodeling the nucleus accumbens, which may underlie post-TBI psychiatric symptoms like impaired decision-making and impulsivity. For neurosurgeons, understanding these circuit-level changes could inform prognostic counseling and potential targets for neuromodulation.
More context
Key details
- Frontal TBI impaired Pavlovian conditioned approach and decision-making on a gambling-like task with cue-reward associations.
- At 14 days post-injury, nucleus accumbens showed increased neuronal excitability, reduced optogenetically-evoked input, and transcriptional upregulation of stress/inflammatory and plasticity genes.
- Chronic effects included reduced c-Fos activity and attenuated cue-evoked calcium signals in the nucleus accumbens during Pavlovian conditioning.
Policy & Systems / Advocacy
75 Medical Groups Urge Senate to Protect Medicare Access in Budget Reconciliation
News • Policy & Systems / Advocacy • CNS • 2025-06-25
Why it matters
This coalition letter, including the CNS, signals a unified front to prevent Medicare payment cuts that directly impact neurosurgery reimbursement and patient access. The budget reconciliation process is a critical legislative vehicle where physician payment policies may be decided.
More context
Key details
- 75 medical organizations signed a letter urging the Senate to protect Medicare access during budget reconciliation.
- The letter likely addresses scheduled payment cuts or reforms to the Medicare Physician Fee Schedule.
- The CNS is among the signatories, reflecting neurosurgery's stake in Medicare policy.
Conferences & Courses
AANS Annual Scientific Meeting 2028
Conference • Conferences & Courses • Event page • 2026-05-03
Why it matters
The AANS Annual Scientific Meeting is the premier neurosurgery conference in North America, featuring the latest research, surgical techniques, and policy updates.
CNS Annual Meeting 2026
Conference • Conferences & Courses • Event page • 2026-05-03
Why it matters
The 76th CNS Annual Meeting features keynote speakers Lindsey Vonn, Sal Khan, and Charles Duhigg, with Honored Guests Gail Rosseau and Ron L. Alterman.